低剂量阿替普酶(0.6mg/kg)静脉溶栓治疗急性缺血性卒中及神经功能改善观察

详细信息    查看全文 | 推荐本文 |

英文篇名：Observation of Low-Dose Alteplase Intravenous Thrombolytic Therapy in the Treatment of Acute Ischemic Stroke and Improvement of Neurological Function 作者：胡列计 ; 候文仲 ; 黄俊士 英文作者：Hu Lieji;Second Area of Department of Brain, Qingyuan People's Hospital; 关键词：低剂量阿替普酶 ; 标准剂量阿替普酶 ; 静脉溶栓 ; 急性缺血性卒中 ; 神经功能 英文关键词：low-dose alteplase;;standard dose of alteplase;;intravenous thrombolysis;;acute ischemic stroke;;neurological function 中文刊名：SLYY 英文刊名：Journal of Mathematical Medicine 机构：清远市人民医院脑科二区; 出版日期：2019-07-05 出版单位：数理医药学杂志 年：2019 期：v.32 语种：中文; 页：SLYY201907039 页数：3 CN：07 ISSN：42-1303/R 分类号：90-92

摘要

目的:探讨低剂量阿替普酶(0.6mg/kg)静脉溶栓治疗急性缺血性卒中及神经功能改善效果。方法:择取某院于2018年9月～2019年3月期间收治的急性缺血性卒中患者共30例,随机分成低剂量组15例(0.6mg/kg)及标准剂量组15例(0.9mg/kg),比较两组患者临床疗效、出血风险、治疗前后神经功能缺损评分(NIHSS)及改良Rankin量表(mRS)评分。结果:两组患者治疗前NIHSS、mRS评分差异无统计学意义(P>0.05),治疗后两组患者NIHSS、mRS评分均显著低于同组治疗前,差异有统计学意义(P<0.05),组间比较差异无统计学意义(P>0.05);低剂量组患者临床疗效80.00%,标准剂量组患者临床疗效86.67%,差异无统计学意义(P>0.05);低剂量组出血风险6.67%低于标准剂量组40.00%,差异有统计学意义(P<0.05)。结论:低剂量阿替普酶溶栓治疗急性缺血性卒中疗效和标准剂量具有一致性,修复神经功能缺损效果相近,但是出血风险更低,值得推广。
        Objective: To explore the effect of low-dose alteplase intravenous thrombolytic therapy in the treatment of acute ischemic stroke and improvement of neurological function. Methods: A total of 30 patients with acute ischemic stroke admitted and treated in a hospital from September 2018 to March 2019 were selected and randomly divided into low-dose group(0.6 mg/kg) with 15 cases and standard dose group with 15 cases(0.9 mg/kg). The clinical efficacy, bleeding risk, neurological impairment score(NIHSS) and modified Rankin scale(mRS) score before and after the treatment of the two groups were compared. Results: There was no significant difference in NIHSS and mRS scores between the two groups before the treatment(P>0.05). After treatment, the NIHSS and mRS scores of the two groups were significantly lower than those of the same group, with statistical significance(P<0.05), there was no significant difference between the two groups(P>0.05); The clinical efficacy was 80.00% in the low-dose group and 86.67% in the standard dose group, with no statistically significant difference(P>0.05); The bleeding risk of the low-dose group was 6.67% lower than that of the standard dose group(40.00%), and the difference was statistically significant(P<0.05).Conclusion:Low-dose alteplase intravenous thrombolytic therapy in the treatment of acute ischemic stroke is consistent with standard dose,and the effect of repairing neurological deficit is similar,but the risk of bleeding is lower and is worth promoting.

引文

1 朱建建,李骥,邹丽,等.低剂量与标准剂量阿替普酶静脉溶栓治疗高龄急性缺血性脑卒中患者的临床疗效对比.中国临床医学,2018,25(6):945～948.
    2 曲颖,慈淑华.不同剂量阿替普酶在急性缺血性卒中静脉溶栓中的疗效比较.中国实用医药,2018,13(7):110～111.
    3 蓝志龙.不同剂量阿替普酶在急性缺血性脑卒中静脉溶栓治疗中的应用效果.临床合理用药杂志,2017,10(3):12～13;16.
    4 牛向平,张素红,吴桂红.不同剂量阿替普酶在急性缺血性卒中静脉溶栓中的疗效对比.血栓与止血学,2016,22(5):559～560.
    5 韩石誉.不同剂量阿替普酶在急性缺血性卒中静脉溶栓中的应用价值.中国继续医学教育,2016,8(12):151～152.